Lilly, BI resubmit diabetes medication

Share this article:

Lilly and Boehringer Ingelheim are resubmitting their experimental SGLT2 diabetes medication empagliflozen to the FDA.

“We are very pleased to move forward . . . following a FDA inspection of the Boehringer Ingelheim facility,” BI president and CEO Paul Fonteyne said in a statement Tuesday, referring to the CRL that halted the FDA's review.

The European Commission greenlighted the diabetes medication, known as Jardiance, in May.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.